Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Badri, Motasim ^a   Lawn, Stephen D ^a,b   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INDIVIDUALIZATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; VIRUS LOAD; DRUG COMBINATION; DRUG EFFECT; EVALUATION; HEALTH CARE PLANNING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; POVERTY; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; MALE; POVERTY; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 47749143297     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-89     Document Type: Article

References (26)

1. World Health Organization Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector: Progress report, April 2007 WHO, Geneva 2007 http://www.who.int/hiv/toronto2006/ towardsuniversalaccess.pdf (Accessed 24.04.07).
2. Cleary S Boulle A McIntyre D Coetzee D Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township Health Systems Trust: Durban 2004 http://www.hst.org.za/ publications/579 (Accessed March 27, 2006).
3. Badri M Maartens G Mandalia S Bekker LG Penrod JR Platt RW Wood R Beck EJ Cost-effectiveness of highly active antiretroviral therapy in South Africa PLoS Med 2006, 1:e4. 10.1371/journal.pmed.0030004
4. Badri M Cleary S Maartens G Pitt J Bekker LG Orrell C Wood R When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study Antivir Ther 2006, 11:63-72. 16518961
5. World Health Organization HIV/AIDS Programme. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for public health approach 2006 revision http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf Accessed 15 Jan 2007.
6. Colebunders R Moses KR Laurence J Shihab HM Semitala F Lutwama F Bakeera-Kitaka S Lynen L Spacek L Reynolds SJ Quinn TC Viner B Mayanja-Kizza H A new model to monitor the virological efficacy of antiretroviral treatment in resource poor countries Lancet Infect Dis 2006, 6:53-59. 10.1016/S1473-3099(05)70327-3 16377535
7. Lawn SD Orrell C Wood R Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settings Lancet Infect Dis 2006, 7:385-386. 10.1016/S1473-3099(06)70498-4
8. Rodríguez B Sethi AK Cheruvu VK Mackay W Bosch RJ Kitahata M Boswell SL Mathews WC Bangsberg DR Martin J Whalen CC Sieg S Yadavalli S Deeks SG Lederman MM Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection JAMA 2006, 296:1498-506. 10.1001/jama.296.12.1498 17003398
9. Henry WK Tebas P Lane HC Explaining, predicting, and treating HIV-associated CD4 cell loss. After 25 years still a puzzle JAMA 2006, 296:1523-5. 10.1001/jama.296.12.1523 17003402
10. Grabar S Le Moing V Goujard C Leport C Kazatchkine MD Costagliola D Weiss L Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy Ann Intern Med 2000, 133:401-410. 10975957
11. Piketty C Castiel P Belec L Batisse D Si Mohamed A Gilquin J Gonzalez-Canali G Jayle D Karmochkine M Weiss L Aboulker JP Kazatchkine MD Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease AIDS 1998, 12:745-750. 10.1097/ 00002030-199807000-00011 9619806
12. Florence E Lundgren J Dreezen C Fisher M Kirk O Blaxhult A Panos G Katlama C Vella S Phillips A EuroSIDA Study Group Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSida study HIV Med 2003, 4:255-262. 10.1046/ j.1468-1293.2003.00156.x 12859325
13. Pakker NG Kroon ED Roos MT Otto SA Hall D Wit FW Hamann D Ende van der ME Claessen FA Kauffmann RH Koopmans PP Kroon FP ten Napel CH Sprenger HG Weigel HM Montaner JS Lange JM Reiss P Schellekens PT Miedema F Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group AIDS 1999, 13:203-212. 10.1097/00002030-199902040-00008 10202826
14. Jevtovic D Salemovic D Ranin J Pesic I Zerjav S Djurkovic-Djakovic O The dissociation between virologic and immunologic responses to HAART Biomed Pharmacother 2005, 59:446-451. 10.1016/j.biopha.2005.07.006 16140494
15. Bisson GP Gross R Strom JB Rollins C Bellamy S Weinstein R Friedman H Dickinson D Frank I Strom BL Gaolathe T Ndwapi N Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy AIDS, 2006, 20:1613-1619. 16868442
16. Paredes R Mocroft A Kirk O Lazzarin A Barton SE van Lunzen J Katzenstein TL Antunes F Lundgren JD Clotet B Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study Arch Intern Med 2000, 160:1123-1132. 10.1001/archinte.160.8.1123 10789605
17. Mocroft A Ruiz L Reiss P Ledergerber B Katlama C Lazzarin A Goebel FD Phillips AN Clotet B Lundgren JD EuroSIDA study group Virological rebound after suppression on highly active antiretroviral therapy AIDS 2003, 17:1741-1751. 10.1097/00002030-200308150-00003 12891060
18. Paris D Ledergerber B Weber R Jost J Flepp M Opravil M Ruef C Zimmerli S Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort AIDS Res Hum Retroviruses 1999, 15:1631-1638. 10.1089/088922299309676 10606086
19. Grabar S Pradier C Le Corfec E Lancar R Allavena C Bentata M Berlureau P Dupont C Fabbro-Peray P Poizot-Martin I Costagliola D Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor AIDS 2000, 14:141-149. 10.1097/ 00002030-200001280-00009 10708284
20. Fournier S Chaffaut C Maillard A Loze B Lascoux C Gérard L Timsit J David F Bergmann JF Oksenhendler E Sereni D Chevret S Molina JM Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: A prospective cohort study HIV Med 2005, 6:129-134. 10.1111/j.1468-1293.2005.00275.x 15807719
21. Tuboi SH Harrison LH Sprinz E Albernaz RK Schechter M Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil J Acquir Immune Defic Syndr 2005, 40:324-328. 10.1097/01.qai.0000182627.28595.01 16249707
22. Parienti JJ Massari V Descamps D Vabret A Bouvet E Larouzé B Verdon R Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy Clin Infect Dis 2004, 38:1311-1316. 10.1086/383572 15127346
23. Le Moing V Chêne G Carrieri MP Alioum A Brun-Vézinet F Piroth L Cassuto JP Moatti JP Raffi F Leport C Aproco Study Group Predictors of virological rebound in HIV-1 infected patients initiating a protease-containing regimen AIDS 2002, 16:21-29. 10.1097/ 00002030-200201040-00004 11741159
24. Badri M Wilson D Wood R Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: A cohort study Lancet 2002, 359:2059-2064. 10.1016/S0140-6736(02)08904-3 12086758
25. Orrell C Harling G Lawn SD Kaplan R McNally M Bekker LG Wood R Conservation of first line antiretroviral treatment regimen where therapeutic options are limited Antivir Ther 2007, 12:83-88. 17503751
26. Balakrishnan P Solomon S Kumarasamy N Mayer KH Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries Indian J Med Res 2005, 121:345-355. 15817948